Palatin Technologies (PTNT)

$0.08 -0.01 (-12.86%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 4,704,300
Avg Vol 3,219,816
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 25%
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 495 2200
Fax: 609 495 2202
Website: palatin.com
Address:
Cedar Brook Corporate Center, 4-B Cedar Brook Drive, Cranbury, United States
Latest News on PTNT
No data available.